Canaccord analyst Mark Massaro said he was positively surprised that Natera was issued a draft local coverage decision by Palmetto MolDx for its blood-based kidney transplant rejection test, as he sees the news increasing the probability that the test launches with Medicare reimbursement. Even after yesterday’s move higher on this news, Natera shares trade at a “material disconnect” to what the business is actually worth, Massaro contends. He raised his price target on the stock to $27 from $26 and keeps a Buy rating on Natera, adding that the stock “is at the top of our list of top picks for 2019.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.